Literature DB >> 8504621

Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

P Reetze-Bonorden1, J Böhler, E Keller.   

Abstract

The advantages of continuous haemofiltration and haemodialysis over intermittent haemodialysis for the treatment of acute renal failure are well recognised. In intensive care patients, 4 different continuous procedures, arteriovenous and venovenous haemofiltration (CAVH and CVVH) or haemodialysis (CAVHD and CVVHD), are employed. These effective detoxification treatments require knowledge of their influence on drug disposition. Data on kinetics of drugs during continuous treatment are scarce and limited almost exclusively to the oldest and least effective procedure (CAVH). Selected dialysis membranes may adsorb drugs, as in the case of aminoglycosides. In addition, elimination of substances with large molecular weights may vary depending on the pore size of the membrane, as in the case of vancomycin. Thus, even if drug dosages can be based on pharmacokinetic studies, selection of a dialysis membrane not studied may cause unpredictable drug concentrations. With these limitations in mind and considering the available literature on pharmacokinetics in patients with renal failure, general guidelines for drug dosage during continuous renal replacement therapy can be given. In haemofiltration, drug protein binding is the major factor determining sieving, i.e. the appearance of the drug in the ultrafiltrate. In haemodialysis, diffusion is added to ultrafiltration, and therefore the saturation of the combined dialysate and ultrafiltrate will decrease further with increasing dialysate flow rate. In continuous haemofiltration or haemodialysis the extracorporeal clearance can be calculated by multiplying the saturation value (estimated or, better, measured) with the ultrafiltrate and dialysate flow rate. Dividing the extracorporeal clearance by the total clearance (including the nonrenal clearance) gives the fraction of the dose removed due to extracorporeal elimination. Whether dosage recommendations available for anuric patients have to be modified or not can be decided on the basis of this value. In case of high nonrenal clearance, the degree of saturation is without clinical significance. Based on these considerations guidelines have been constructed for the effect of extracorporeal elimination on more than 120 different drugs commonly used in intensive care patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8504621     DOI: 10.2165/00003088-199324050-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  98 in total

1.  Pharmacokinetics of imipenem/cilastatin during continuous arteriovenous hemofiltration.

Authors:  M Przechera; D Bengel; T Risler
Journal:  Contrib Nephrol       Date:  1991       Impact factor: 1.580

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

3.  Elimination kinetics of captopril in patients with renal failure.

Authors:  K L Duchin; A M Pierides; A Heald; S M Singhvi; A J Rommel
Journal:  Kidney Int       Date:  1984-06       Impact factor: 10.612

4.  Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients.

Authors:  B J Zarowitz; J V Anandan; F Dumler; J Jayashankar; N Levin
Journal:  J Clin Pharmacol       Date:  1986 Nov-Dec       Impact factor: 3.126

5.  Norepinephrine clearance, chromogranin A and dopamine beta hydroxylase in renal failure.

Authors:  M G Ziegler; B Kennedy; E Morrissey; D T O'Connor
Journal:  Kidney Int       Date:  1990-05       Impact factor: 10.612

6.  The metabolic disposition of flucloxacillin in patients with impaired kidney function.

Authors:  H H Thijssen; J Wolters
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis.

Authors:  D A Sica; T Comstock; A Harford; F Eshelman
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Pharmacokinetics of cefuroxime and ceftazidime in patients with acute renal failure treated by continuous arteriovenous haemodialysis.

Authors:  S P Davies; L F Lacey; W J Kox; E A Brown
Journal:  Nephrol Dial Transplant       Date:  1991       Impact factor: 5.992

9.  Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis.

Authors:  E Singlas; A M Taburet; I Landru; H Albin; J P Ryckelinck
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 10.  Drug prescribing in renal failure: dosing guidelines for adults.

Authors:  W M Bennett; G R Aronoff; G Morrison; T A Golper; J Pulliam; M Wolfson; I Singer
Journal:  Am J Kidney Dis       Date:  1983-11       Impact factor: 8.860

View more
  32 in total

1.  Pharmacokinetics of isepamicin during continuous venovenous hemodiafiltration.

Authors:  D Breilh; B Allaouchiche; H Jaumain; P Boulétreau; D Chassard; I Malbec; D Ducint; M C Saux
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis.

Authors:  Silke C Mueller; Jolanta Majcher-Peszynska; Heiko Hickstein; Astrid Francke; Annette Pertschy; Martin Schulz; Ralf Mundkowski; Bernd Drewelow
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

3.  Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.

Authors:  Kashyap Patel; Jason A Roberts; Jeffrey Lipman; Susan E Tett; Megan E Deldot; Carl M Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

Review 4.  Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.

Authors:  Arduino A Mangoni
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 5.  Pharmacokinetics of continuous renal replacement therapy.

Authors:  M Schetz; P Ferdinande; G Van den Berghe; C Verwaest; P Lauwers
Journal:  Intensive Care Med       Date:  1995-07       Impact factor: 17.440

6.  Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration.

Authors:  B Allaouchiche; D Breilh; H Jaumain; B Gaillard; S Renard; M C Saux
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 7.  Principles of drug administration in renal insufficiency.

Authors:  Y W Lam; S Banerji; C Hatfield; R L Talbert
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

8.  Dosing nucleoside reverse transcriptase inhibitors in adults receiving continuous veno-venous hemofiltration.

Authors:  Milena M McLaughlin; Abeer T Ammar; Lana Gerzenshtein; Kimberly K Scarsi
Journal:  Clin Drug Investig       Date:  2015-04       Impact factor: 2.859

9.  Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.

Authors:  R S Malone; D N Fish; E Abraham; I Teitelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.

Authors:  Megan E DelDot; Jeffrey Lipman; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.